Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 14
2004 11
2005 14
2006 16
2007 32
2008 21
2009 31
2010 38
2011 27
2012 29
2013 35
2014 22
2015 25
2016 19
2017 15
2018 12
2019 22
2020 20
2021 19
2022 16
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review.
Pradere B, Mallet R, de La Taille A, Bladou F, Prunet D, Beurrier S, Bardet F, Game X, Fournier G, Lechevallier E, Meria P, Matillon X, Polguer T, Abid N, De Graeve B, Kassab D, Mejean A, Misrai V, Pinar U; Sustainability Task Force of the French Association of Urology. Pradere B, et al. Among authors: de la taille a. Eur Urol. 2023 Apr;83(4):331-342. doi: 10.1016/j.eururo.2022.01.027. Epub 2022 Feb 10. Eur Urol. 2023. PMID: 35151515 Free article. Review.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Beltran H, et al. Among authors: de la taille a. Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130. Cancer Discov. 2011. PMID: 22389870 Free PMC article.
Stroma in normal and cancer wound healing.
Huet E, Jaroz C, Nguyen HQ, Belkacemi Y, de la Taille A, Stavrinides V, Whitaker H. Huet E, et al. Among authors: de la taille a. FEBS J. 2019 Aug;286(15):2909-2920. doi: 10.1111/febs.14842. Epub 2019 Apr 15. FEBS J. 2019. PMID: 30958920 Free article. Review.
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial.
Sapoval M, Thiounn N, Descazeaud A, Déan C, Ruffion A, Pagnoux G, Duarte RC, Robert G, Petitpierre F, Karsenty G, Vidal V, Murez T, Vernhet-Kovacsik H, de la Taille A, Kobeiter H, Mathieu R, Heautot JF, Droupy S, Frandon J, Barry Delongchamps N, Korb-Savoldelli V, Durand-Zaleski I, Pereira H, Chatellier G; PARTEM study group. Sapoval M, et al. Among authors: de la taille a. Lancet Reg Health Eur. 2023 Jun 26;31:100672. doi: 10.1016/j.lanepe.2023.100672. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37415648 Free PMC article.
The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
Blanc C, Moktefi A, Jolly A, de la Grange P, Gay D, Nicolaiew N, Semprez F, Maillé P, Soyeux P, Firlej V, Vacherot F, Destouches D, Amiche M, Terry S, de la Taille A, Londoño-Vallejo A, Allory Y, Delbé J, Hamma-Kourbali Y. Blanc C, et al. Among authors: de la taille a. Br J Cancer. 2023 Mar;128(5):918-927. doi: 10.1038/s41416-022-02114-9. Epub 2022 Dec 22. Br J Cancer. 2023. PMID: 36550208 Free PMC article.
Urine biomarkers in prostate cancer.
Ploussard G, de la Taille A. Ploussard G, et al. Among authors: de la taille a. Nat Rev Urol. 2010 Feb;7(2):101-9. doi: 10.1038/nrurol.2009.261. Epub 2010 Jan 12. Nat Rev Urol. 2010. PMID: 20065953 Review.
376 results